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Abstract
Context: Circulating levels of metabolically protective and adverse cytokines are altered in obese humans and
rodent models. However, it is not clear whether these cytokines are altered rapidly in response to over-nutrition, or as
a later consequence of the obese state.
Methods: Forty sedentary healthy individuals were examined prior to and at 3 and 28 days of high fat overfeeding
(+1250 kCal/day, 45% fat). Insulin sensitivity (hyperinsulinaemic-euglycaemic clamp), adiposity, serum levels of
adiponectin and fibroblast growth factor-21 (FGF21), fatty acid binding protein-4 (FABP4), lipocalin-2 and
plasminogen activator factor-1 (PAI1) were assessed. Statistics were performed by repeated measures ANOVA.
Results: Overfeeding increased weight, body fat and liver fat, fasting glucose, insulin and reduced insulin sensitivity
by clamp (all P <0.05). Metabolically protective cytokines, adiponectin and FGF21 were increased at day 3 of
overfeeding (P ≤0.001) and adiponectin was also elevated at day 28 (P=0.001). FABP4, lipocalin-2 and PAI-1 were
not changed by overfeeding at either time point.
Conclusion: Metabolically protective cytokines, adiponectin and FGF-21, were increased by over nutrition and
weight gain in healthy humans, despite increases in insulin resistance. We speculate that this was in attempt to
maintain glucose homeostasis in a state of nutritional excess. PAI-I, FABP4 and lipocalin 2 were not altered by
overfeeding suggesting that changes in these cytokines may be a later consequence of the obese state.
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Introduction
Obesity is associated with increased secretion of
metabolically adverse adipokines such as fatty acid binding
protein-4 (FABP4) and reduced secretion of metabolically
protective adipokines such as adiponectin [1]. Obesity is also
associated with ectopic lipid deposition in the liver [2] and
altered secretion of cytokines from the liver. Whilst the exact
target and function of many novel cytokines remain to be
elucidated, there is increasing evidence to suggest direct
involvement in the pathogenesis of insulin resistance [3].
Adiponectin is an abundantly produced adipokine that is
inversely related to adiposity, and exerts protective anti-
inflammatory and anti-apoptotic effects that improve insulin
sensitivity and reduce oxidative stress [4]. FABP4 is a lipid
binding chaperone that interacts with hormone sensitive lipase
in adipose tissue to facilitate lipolysis [5]. FABP4 is also
released from adipocytes [6], although the mechanism, target
and function of the secreted form of FABP4 is not clear.
Circulating levels of FABP4 are positively correlated with
obesity and non-alcoholic fatty liver [7] and predict the
development of metabolic syndrome and type 2 diabetes [8].
Moreover, FABP4 disruption decreases insulin resistance,
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e78864
dyslipidemia and liver steatosis in obese or fat fed animals [9].
Lipocalin-2 was originally identified in human neutrophils, but is
also secreted from adipose tissue, macrophages, liver, lung,
and kidney and is involved in the inflammatory response [10].
Lipocalin-2 is elevated in obesity, diabetes and non-alcoholic
fatty liver disease [7,11]. Plasminogen activator inhibitor-1
(PAI-1) is expressed in many tissues including visceral and
subcutaneous adipose tissue depots, although adipose tissue-
resident macrophages may be the primary source of this
cytokine in these depots [12]. PAI-1 is the prime regulator of
fibrinolysis and subjects with increased levels of PAI-1 are
predisposed to atherothrombotic events [12]. Obese patients
with and without type 2 diabetes have elevated levels of PAI-1
as compared to lean individuals and this is closely linked with
insulin resistance [13].
Like adiponectin, the recently discovered and predominately
liver derived cytokine, fibroblast growth factor-21 (FGF21) is
considered to be metabolically protective. Over-expression or
treatment with recombinant FGF21 protects mice from
development of obesity and fatty liver and improves insulin
sensitivity [3] and comparable metabolic benefits are also
observed in rhesus monkeys [14]. Paradoxically, FGF21 levels
are elevated in obesity [15] and obese mice treated with
recombinant FGF21 have a blunted metabolic response to
FGF21, which suggests that resistance to the actions of FGF21
may develop in obesity [16].
Short term overfeeding provides a model to examine whether
cytokines are altered rapidly in response to over-nutrition. In
this cohort, we have previously reported that short term
overfeeding does not alter macrophage infiltration of adipose
tissue, although increases in C-reactive protein (CRP) and
macrophage chemo-attractant protein-1 (MCP1) were identified
[17]. Here, we examined the relationships between adiposity
and insulin resistance and circulating levels of adiponectin,
FABP4, lipocalin-2, PAI-1 and FGF21 before and after high fat
overfeeding for 28 days.
Methods
Subjects and Study Design
The study was approved by the Human Research and Ethics
Committee of St Vincent’s Hospital and registered as a Clinical
Trial at clinicaltrials.gov, registration number NCT00562393, all
participants signed informed consent prior to the study. The
study protocol and CONSORT diagram is described previously
[18,19] and this analysis includes the entire cohort as
previously reported.
The cohort consisted of 20 women (5 post-menopausal) and
20 men, mean age 37 years (range 21-59 years); 17 subjects
reported a family history of type 2 diabetes. All subjects were
healthy, sedentary and not taking any medications. All foods
were provided for 3-days before metabolic testing at baseline,
day 3 and study end as described previously [18]. At baseline,
this was at calculated energy requirements, with a nutrient
composition of 30% fat, 15% protein and 55% carbohydrate.
During the first and last 3 days of overfeeding, all foods were
provided at 1250 kcal/day above calculated energy
requirements, with a nutrient composition of 45% fat, 15%
protein and 40% carbohydrate. During the remainder of the
overfeeding phase (days 3 - 25), subjects were asked to
consume their regular diet with high fat snacks provided to
increase energy intake by 1250 kcal/day. Average (± SEM)
reported energy intakes during the self-selecting phase
increased from 1980 ± 110 to 3100 ± 140 kcal/d and the
contribution of fat from 34 ± 1 at baseline to 45 ± 1 %. Weight
gain and compliance were monitored weekly by the research
nurse and dietician.
Metabolic Testing at Baseline and after 28 Days of
Overfeeding
All metabolic tests were conducted at the Clinical Research
Facility at the Garvan Institute of Medical Research after a 12h
overnight fast. Weight was measured in a hospital gown after
voiding. Height, blood pressure, waist and hip circumference
were also measured. Fasting blood samples were drawn and
insulin sensitivity was assessed by a 2-h hyperinsulinaemic-
euglycaemic clamp (60 mU/m2/min), as described [18]. Steady
state glucose infusion rate (GIR) between 90 and 120 min of
the clamp procedure was averaged and normalized for body fat
free mass (FFM). Resting metabolic rate and respiratory
quotient were assessed by True One metabolic cart following
30 minutes of supine rest (ParvoMedics, UT, USA). Body
composition was measured by dual energy x-ray
absorptiometry (DXA; Lunar DPX GE Lunar, Lunar Corp.,
Madison, WI). Three cross-sectional computed tomography
(CT) scans (Phillips Gemini GXL), 1 cm-width, centered on the
L2-L3 and L4-L5 disc space, and the T12-L1 disc space were
also performed to assess abdominal adipose tissue distribution
and hepatic fat content as described [18]. An additional blood
sample for fasting levels of glucose, insulin and cytokines was
taken at 3 days of overfeeding.
Biochemical variables
Blood glucose was determined by the glucose oxidase
method (Glucose analyzer 2300 STAT PLUS 230V, YSI, Inc.,
Yellow Springs, OH, USA), serum insulin by radioimmunoassay
(Linco, St. Charles, MO, USA) and serum non-esterified fatty
acid (NEFA) by enzymatic colorimetric assay (Wako, Osaka,
Japan). Adiponectin, lipocalin-2, PAI-1, FGF-21, and FABP4
were determined by immunoassays established by Antibody
and Immunoassay Services, the University of Hong Kong
[20-23].. The observed intra and inter assay CVs were 3.2%
and 4.6%, 4.3% and 6.2%, 3.7% and 5.8%, 5.2% and 6.7%,
and 4.5% and 6.3% respectively.
Statistical Analysis
Data are presented as mean ± SEM unless otherwise stated.
FABP4 and insulin data were log10-transformed prior to
statistical analysis. Since no differences were detected for any
markers of inflammation at baseline or in response to
overfeeding between individuals with and without a family
history of type 2 diabetes, these groups were combined. The
effects of overfeeding were tested using repeated measures-
ANOVA with gender as the between-subject factor. In case of
significance a paried t test was used to evaluate differences
between time-points. Pearson’s correlations were performed
Adiponectin, FGF-21 and Overfeeding in Humans
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and partial correlations were used to adjust for gender. Sample
size requirements were calculated for primary endpoint ∆
(glucose infusion rate/kg FFM) using 2 sided within subject
contrasts with α<0.05 and statistical power 1-β>0.8. Statistical
Package for Social Sciences (SPSS) version 21 (Chicago, IL)
was used, without adjustment for multiplicity.
Results
Cytokine levels by gender and relationships with
adiposity
At baseline, significantly higher serum concentrations of
FABP4 and adiponectin, and lower serum concentrations of
FGF21 were observed in women (Table 1). FABP4 was closely
correlated with fasting insulin (Figure 1A), body fat (Figure 1B),
BMI (r2=0.22, P=0.002), abdominal subcutaneous (r2=0.4, P
<0.001) and visceral adipose tissue (r2=0.15, P=0.02) and
serum NEFA (r2=0.27, P <0.001). These associations remained
significant following adjustment for gender (all P ≤0.02). Serum
adiponectin was inversely correlated with visceral adipose
tissue (Figure 1C) and positively with fasting NEFA (Figure
1D), although significance was lost after adjusting for gender.
We did not detect any relationships between lipocalin-2, PAI-1,
or FGF-21 and measures of adiposity, NEFA or insulin
sensitivity, although a positive relationship was observed
between FGF21 and the respiratory quotient (r2=0.26,
P=0.002), which remained significant after adjusting for gender
(P=0.008).
Metabolic consequences of overfeeding
Anthropometric and metabolic measures at baseline and
after 28 days of overfeeding are summarized in Table 2.
Overfeeding induced significant weight gain (2.7 ± 0.3 kg, P
<0.001). Similarly, BMI, percent body fat, abdominal
subcutaneous and visceral adipose tissue and liver fat were
significantly increased by overfeeding (Table 2, all P <0.01).
Fasting glucose and insulin increased at both 3 and 28 days (P
<0.01) and fasting NEFA decreased transiently at day 3
(P<0.001) and returned to baseline levels at day 28 (P=0.4).
Insulin sensitivity by hyperinsulinemic clamp and HOMA-IR
was reduced (P=0.03 and P<0.001, respectively). Resting
metabolic rate (RMR) increased significantly (P≤0.003) and the
respiratory quotient (RQ) increased significantly at day 3
(P<0.001) and returned to baseline levels on day 28 (P=0.2).
Table 1. Gender differences in cytokine levels at baseline.
 Men Women P-Value
FABP4 (µg/L) 19.6 ± 2.9 28.9 ± 3.1 0.02
Adiponectin (mg/L) 10.3 ± 0.9 18.7 ± 1.2 <0.001
FGF21 (ng/L) 81.8 ± 13.5 48.3 ± 8.5 0.04
Lipocalin-2 (µg/L) 30.3 ± 4.0 27.9 ± 2.7 0.6
PAI-1 (µg/L) 6.0 ± 0.6 5.9 ± 0.6 0.9
Data are mean ± SEM
FABP4 data were log10-transformed prior to statistical analysis
doi: 10.1371/journal.pone.0078864.t001
Overfeeding transiently increased serum levels of FGF21 at
day 3 (P=0.001, Figure 2A) and increased adiponectin levels at
day 3 and day 28 (P ≤0.001, Figure 2B). The responses in
serum adiponectin were independent of gender (P >0.2 for
both), but FGF21 was increased to a greater extent in men at
day 3 (P=0.04). No statistically significant changes were
detected in lipocalin-2 (P=0.1, Figure 2C), FABP4 (P=0.7,
Figure 2D) and PAI-1 (P=0.4, Figure 2E).
Of the cytokines examined, only the change in adiponectin
was correlated with weight gain and change in BMI at day 28
(Figure 3A and B, respectively). The change in FGF21 was
positively related to the change in resting energy expenditure
(Figure 3C) and the change in FABP4 correlated with the
change in NEFA (Figure 3D). The change in PAI-1 and
lipocalin-2 were not correlated with changes in any metabolic
variable measured in response to overfeeding.
Discussion
The secretion profile of pro and anti-inflammatory cytokines
is altered in obesity and may directly impact insulin sensitivity.
However, it is not clear if changes occur as an early event in
response to overfeeding and insulin resistance, or as a later
consequence of the obese state. In this study, we show that
overfeeding resulted in weight gain, increased lipid deposition
in adipose tissue and liver and reduced insulin sensitivity. In
parallel, increases in metabolically protective cytokines
adiponectin and FGF21 were observed. No changes were
detected in the metabolically adverse cytokines FABP4, PAI-1
and lipocalin-2, suggesting that these may be altered as a later
consequence of the obese state.
Adiponectin is primarily produced by the adipocyte and acts
as a metabolically protective cytokine, with beneficial actions
not only on insulin sensitivity, but also on the cardiovascular
system [4]. Circulating adiponectin concentrations are not
changed in response to a single high fat meal [24]. However,
weight loss significantly increases circulating adiponectin [25].
Here, we observed that total adiponectin levels were increased
in response to short-term overfeeding and weight gain. This is
also previously reported after 5 days of high fat overfeeding in
lean young men [26], thus we confirm and extend these
findings to show elevations are sustained at least to 28 days in
healthy humans. Moreover, we observed that the increase in
adiponectin was correlated with the amount of weight gained
during overfeeding. Whilst this response appears
counterintuitive, since insulin sensitivity was reduced, it may be
the metabolically healthy response in an attempt to maintain an
anti-inflammatory profile and glucose homeostasis in liver and
muscle. However, it should be noted that adiponectin circulates
in multimeric forms [4], with the high molecular weight (HMW)
being the biologically active form, which was not assessed in
this study.
FGF21 is also postulated to be a metabolically protective
cytokine since treatment with FGF21 mimetics protects against
obesity, fatty liver and insulin resistance in mouse and primates
[3,14]. Weight loss does not alter FGF21 levels in obese
humans [27], but FGF21 is increased in response to 24-hours
of fasting in mice and stimulates adipose tissue lipolysis and
Adiponectin, FGF-21 and Overfeeding in Humans
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lipid metabolism [28]. In humans, fasting for between 1-3 days
did not alter FGF21 [29,30], but fasting for 7 days significantly
increased FGF21 [31]. FGF21 was also increased by lipid-
heparin infusion which concurrently increased NEFA above 1.5
Figure 1.  Relationships between circulating fatty acid binding protein 4 and fasting insulin (A) and percent body fat by
DXA (B), and between adiponectin and visceral adipose tissue (C) and fasting serum non-esterified fatty acid (D) in men
(empty circles) and women (dark circles).  Depicted are the line of fit and the 95% confidence curves that were obtained from
linear regression.
Abbreviations: FABP4, fatty acid binding protein 4; AT, adipose tissue; NEFA, non-esterified fatty acid.
doi: 10.1371/journal.pone.0078864.g001
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mmol/L [32]. These studies suggest that under conditions of
increased delivery of fatty acids to the liver, FGF21 is
increased and promotes lipid oxidation. Supporting this
concept, high fat liquid gavage also increased expression of
FGF21 in mouse liver [33]. In this study, we observed a
transient increase in circulating FGF21 after 3-days of
overfeeding and a similar finding has been reported in healthy
men after 5 days of overfeeding [34]. This supports the notion
that FGF21 is increased by conditions that likely promoted
increased delivery of fatty acids to the liver. However, we do
not have evidence of a role for FGF21 in promoting lipid
oxidation under these conditions. Rather, FGF21 was
increased alongside an increase in glucose oxidation at day 3
and returned to baseline despite an increase in measured lipid
content in the liver at day 28. Additionally, we also observed a
positive relationship between FGF21 and respiratory quotient
at baseline. Whilst this is based on correlational analysis only,
Table 2. Anthropometric and metabolic responses to
overfeeding.
  Overfeeding
 Baseline 3-days 28-days
Weight (kg) 75.3±1.9 75.9±1.9** 78.1±1.9**
BMI (kg/m2) 25.6±0.6 25.8±3.6** 26.6±3.6**
Total body fat (%) 34±1 NA 35±1**
Abdominal subcutaneous fat (cm2) 256 ± 17 NA 276 ± 17**
Abdominal visceral fat (cm2) 77 ± 8 NA 86 ± 8**
Liver density (HU)# 55 ± 2 NA 53 ± 2**
Glucose (mmol/L) 4.5±0.06 4.7±0.06** 4.6±0.05*
Fasting insulin (pmol/L) 65.5±3.3 80.3±4.5** 77.2±3.6**
Fasting NEFA (mmol/L) 0.30 ± 0.02 0.19 ± 0.02** 0.30 ± 0.02
HOMA-IR 1.8±0.1 2.3±0.1** 2.2±0.1**
GIR (µmol/KgFFM/min) 54.8±2.8 NA 50.3±2.5*
Resting metabolic rate (kcal/day) 1378 ± 38 1454 ± 42** 1452 ± 42**
Respiratory quotient 0.81 ± 0.01 0.85 ± 0.01** 0.82 ± 0.01
Data are mean ± SEM
Difference from baseline *P <0.05, **P <0.01
#Liver density in Houndsfeld Units (HU) is inversely proportional to liver fat, (NA)
not assessed at day 3.
Insulin data were log10-transformed prior to statistical analysis
Abbreviations: BMI, body mass index; NEFA, non-esterified fatty acids; HOMA-IR,
homeostasis model assessment of insulin resistance; GIR, glucose infusion rate;
FFM, fat free mass.
doi: 10.1371/journal.pone.0078864.t002
there is some evidence to support the concept that FGF21 may
be regulated by both fasting and feeding signals, since the
promoter region not only has a peroxisome proliferator
activated receptor-α (PPARα) element that responds to fatty
acids but a carbohydrate response element (ChREBP) that
responds to glucose [35]. Of note however, FGF21 is also
increased by changes in glucagon [36], which are known to be
increased by overfeeding in humans [37]. Further study into the
role of FGF21 under conditions of energy excess in humans is
required.
Serum levels of FABP4 are elevated in obesity and
metabolic syndrome and may contribute to development of
nonalcoholic steatohepatitis (NASH) [38]. We also observed
relationships between serum FABP4 and numerous measures
of adiposity and insulin resistance at baseline. However,
FABP4 was not changed in response to overfeeding and
moderate weight gain, suggesting that this is not nutritionally
regulated or responsive to acute gains in liver fat. Our results
are in contrast to previous studies that have reported that
moderate exercise and weight losses produce small reductions
in FABP4 [39], but are in line with reports in mouse that show
elevations in FABP4 are aligned with models of NASH rather
than fatty liver per se [33]. Lipocalin-2 is elevated in animal
models of obesity and in obese humans [11]. However, the
results from studies into the phenotype of the lipocalin-2
knockout mouse are mixed, with reports of no phenotype, as
well as protection from and promotion of an obesity phenotype
and insulin resistance [40-42]. Weight loss may reduce
lipocalin-2 in humans [43], however this is not observed
consistently [39]. In this study, we did not observe any
relationship between lipocalin-2 and adiposity or insulin
resistance at baseline. Similarly, we did not observe any
relationships between obesity and PAI-1. Both may simply
reflect the narrow BMI band investigated. However, we also
observed no change in PAI-1 or lipocalin-2 in response to
overfeeding and insulin resistance. In this cohort, short term
overfeeding did not alter macrophage infiltration of adipose
tissue [17], and therefore we suggest that PAI-1 and lipocalin-2
may be elevated as a consequence of macrophage infiltration
of adipose tissue in the obese state [1].
In summary, over-nutrition increased body weight and
markers of insulin resistance in healthy humans. Serum levels
of adiponectin and FGF-21 were increased by overfeeding,
possibly in an attempt to maintain insulin sensitivity. PAI-I,
FABP4 and lipocalin 2 were not altered by overfeeding and
moderate weight gain suggesting that changes in these
cytokines are a later consequence of the obese state.
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Figure 2.  Serum concentrations of fibroblast growth factor 21 (A), adiponectin (B), lipocalin-2 (C), fatty acid binding
protein 4 (D) and plasminogen activating inhibitor 1 (E) at baseline and in response to overfeeding in healthy humans.  *P
<0.05, **P ≤0.001. FABP4 data were log10-transformed prior to statistical analysis.
doi: 10.1371/journal.pone.0078864.g002
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Figure 3.  Associations between the change in adiponectin and change in weight (A) and BMI (B) and between the change
in fatty acid binding protein 4 and change in fasting non-esterified fatty acid (C) and between the change in fibroblast
growth factor 21 and resting metabolic rate (D) with overfeeding in men (empty circles) and women (dark circles).  Change
was calculated as day 28 minus baseline (∆). Depicted are the line of fit and the 95% confidence curves that were obtained from
linear regression.
Abbreviations: BMI, body mass index; FABP4, fatty acid binding protein 4; FGF21, fibroblast growth factor 21; RMR, resting
metabolic rate.
doi: 10.1371/journal.pone.0078864.g003
Adiponectin, FGF-21 and Overfeeding in Humans
PLOS ONE | www.plosone.org 7 October 2013 | Volume 8 | Issue 10 | e78864
Acknowledgements
Our thanks go to the staff at the Garvan Clinical Research
Facility, and in particular the study coordinator, Ms Schofield
and Dr Greenfield, Viardot and Tonks, and the volunteers who
participated in this demanding research study.
Author Contributions
Conceived and designed the experiments: LKH LVC DSB.
Performed the experiments: AZ. Analyzed the data: LKH DSB.
Contributed reagents/materials/analysis tools: AZ. Wrote the
manuscript: LKH DSB.
References
1. Heilbronn LK, Campbell LV (2008) Adipose tissue macrophages, low
grade inflammation and insulin resistance in human obesity. Curr
Pharm Des 14: 1225-1230. doi:10.2174/138161208784246153.
PubMed: 18473870.
2. Kotronen A, Yki-Järvinen H (2008) Fatty liver: a novel component of the
metabolic syndrome. Arterioscler Thromb Vasc Biol 28: 27-38.
PubMed: 17690317.
3. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R et
al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115:
1627-1635. doi:10.1172/JCI23606. PubMed: 15902306.
4. Hickman IJ, Whitehead JP (2012) Structure, signalling and physiologic
role of adiponectin-dietary and exercise- related variations. Curr Med
Chem 19: 5427-5443. doi:10.2174/092986712803833155. PubMed:
22876920.
5. Makowski L, Hotamisligil GS (2005) The role of fatty acid binding
proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol
16: 543-548. doi:10.1097/01.mol.0000180166.08196.07. PubMed:
16148539.
6. Xu A, Wang Y, Xu JY, Stejskal D, Tam S et al. (2006) Adipocyte fatty
acid-binding protein is a plasma biomarker closely associated with
obesity and metabolic syndrome. Clin Chem 52: 405-413. doi:10.1373/
clinchem.2005.062463. PubMed: 16423904.
7. Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG et al.
(2009) Adipocyte fatty acid binding protein levels relate to inflammation
and fibrosis in nonalcoholic fatty liver disease. Hepatology 49:
1926-1934. doi:10.1002/hep.22896. PubMed: 19475694.
8. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM et al. (2007) Circulating
adipocyte-fatty acid binding protein levels predict the development of
the metabolic syndrome: a 5-year prospective study. Circulation 115:
1537-1543. doi:10.1161/CIRCULATIONAHA.106.647503. PubMed:
17389279.
9. Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M et al. (2005)
Adipocyte/macrophage fatty acid binding proteins control integrated
metabolic responses in obesity and diabetes. Cell Metab 1: 107-119.
doi:10.1016/j.cmet.2004.12.008. PubMed: 16054052.
10. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA et al. (2004)
Lipocalin 2 mediates an innate immune response to bacterial infection
by sequestrating iron. Nature 432: 917-921. doi:10.1038/nature03104.
PubMed: 15531878.
11. Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J et al. (2007)
Lipocalin-2 is an inflammatory marker closely associated with obesity,
insulin resistance, and hyperglycemia in humans. Clin Chem 53: 34-41.
PubMed: 17040956.
12. Alessi M-C, Juhan-Vague I (2006) PAI-1 and the Metabolic Syndrome:
Links, Causes, and Consequences. Arterioscler Thromb Vasc Biol 26:
2200-2207. doi:10.1161/01.ATV.0000242905.41404.68. PubMed:
16931789.
13. Schneider DJ, Sobel BE (2012) PAI-1 and Diabetes: A Journey From
the Bench to the Bedside. Diabetes Care 35: 1961-1967. doi:10.2337/
dc12-0638. PubMed: 22996180.
14. Foltz IN, Hu S, King C, Wu X, Yang C et al. (2012) Treating Diabetes
and Obesity with an FGF21-Mimetic Antibody Activating the βKlotho/
FGFR1c Receptor Complex. Sci Transl Med 4: 162ra153. PubMed:
23197570.
15. Zhang X, Yeung DCY, Karpisek M, Stejskal D, Zhou Z-G et al. (2008)
Serum FGF21 Levels Are Increased in Obesity and Are Independently
Associated With the Metabolic Syndrome in Humans. Diabetes 57:
1246-1253. doi:10.2337/db07-1476. PubMed: 18252893.
16. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A et al.
(2010) Obesity is a fibroblast growth factor 21 (FGF21)-resistant state.
Diabetes 59: 2781-2789. doi:10.2337/db10-0193. PubMed: 20682689.
17. Tam CS, Viardot A, Clément K, Tordjman J, Tonks K et al. (2010)
Short-Term Overfeeding May Induce Peripheral Insulin Resistance
Without Altering Subcutaneous Adipose Tissue Macrophages in
Humans. Diabetes 59: 2164-2170. doi:10.2337/db10-0162. PubMed:
20547978.
18. Samocha-Bonet D, Campbell LV, Viardot A, Freund J, Tam CS et al.
(2010) A family history of type 2 diabetes increases risk factors
associated with overfeeding. Diabetologia 53: 1700-1708. doi:10.1007/
s00125-010-1768-y. PubMed: 20461357.
19. Samocha-Bonet D, Campbell LV, Mori TA, Croft KD, Greenfield JR et
al. (2012) Overfeeding reduces insulin sensitivity and increases
oxidative stress, without altering markers of mitochondrial content and
function in humans. PLOS ONE 7: e36320. doi:10.1371/journal.pone.
0036320. PubMed: 22586466.
20. Ong KL, Rye K-A, O'Connell R, Jenkins AJ, Brown C et al. (2012)
Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21
and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. J Clin
Endocrinol Metab 97: 4701-4708. doi:10.1210/jc.2012-2267. PubMed:
23144467.
21. Xiao Y, Xu A, Hui X, Zhou P, Li X et al. (2013) Circulating Lipocalin-2
and Retinol-Binding Protein 4 Are Associated with Intima-Media
Thickness and Subclinical Atherosclerosis in Patients with Type 2
Diabetes. PLOS ONE 8: e66607. doi:10.1371/journal.pone.0066607.
PubMed: 23799122.
22. Yu H, Xia F, Lam KSL, Wang Y, Bao Y et al. (2011) Circadian Rhythm
of Circulating Fibroblast Growth Factor 21 Is Related to Diurnal
Changes in Fatty Acids in Humans. Clin Chem 57: 691-700. doi:
10.1373/clinchem.2010.155184. PubMed: 21325103.
23. Li H, Dong K, Fang Q, Hou X, Zhou M et al. (2013) High serum level of
fibroblast growth factor 21 is an independent predictor of non-alcoholic
fatty liver disease: A 3-year prospective study in China. J Hepatol 58:
557-563. doi:10.1016/S0168-8278(13)61386-0. PubMed: 23142063.
24. Peake PW, Kriketos AD, Denyer GS, Campbell LV, Charlesworth JA
(2003) The postprandial response of adiponectin to a high-fat meal in
normal and insulin-resistant subjects. Int J Obes 27: 657-662. doi:
10.1038/sj.ijo.0802289. PubMed: 12833108.
25. Pasarica M, Tchoukalova YD, Heilbronn LK, Fang X, Albu JB et al.
(2009) Differential effect of weight loss on adipocyte size subfractions
in patients with type 2 diabetes. Obesity (Silver Spring) 17: 1976-1978.
doi:10.1038/oby.2009.219. PubMed: 19629054.
26. Brøns C, Jensen CB, Storgaard H, Hiscock NJ, White A et al. (2009)
Impact of short-term high-fat feeding on glucose and insulin metabolism
in young healthy men. J Physiol 587: 2387-2397. doi:10.1113/jphysiol.
2009.169078. PubMed: 19332493.
27. Mai K, Schwarz F, Bobbert T, Andres J, Assmann A et al. (2011)
Relation between fibroblast growth factor-21, adiposity, metabolism,
and weight reduction. Metabolism 60: 306-311. doi:10.1016/j.metabol.
2010.02.016. PubMed: 20362303.
28. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS et al. (2007)
Hepatic Fibroblast Growth Factor 21 Is Regulated by PPARα and Is a
Key Mediator of Hepatic Lipid Metabolism in Ketotic States. Cell Metab
5: 426-437. doi:10.1016/j.cmet.2007.05.002. PubMed: 17550778.
29. Andersen B, Beck-Nielsen H, Højlund K (2011) Plasma FGF21 displays
a circadian rhythm during a 72-h fast in healthy female volunteers. Clin
Endocrinol 75: 514-519. doi:10.1111/j.1365-2265.2011.04084.x.
PubMed: 21521350.
30. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M et
al. (2010) Increased fibroblast growth factor 21 in obesity and
nonalcoholic fatty liver disease. Gastroenterology 139: 456-463. doi:
10.1053/j.gastro.2010.04.054. PubMed: 20451522.
31. Gälman C, Lundåsen T, Kharitonenkov A, Bina HA, Eriksson M et al.
(2008) The Circulating Metabolic Regulator FGF21 Is Induced by
Prolonged Fasting and PPAR± Activation in Man. Cell Metab 8:
169-174. doi:10.1016/j.cmet.2008.06.014. PubMed: 18680716.
32. Mai K, Bobbert T, Groth C, Assmann A, Meinus S et al. (2010)
Physiological modulation of circulating FGF21: relevance of free fatty
acids and insulin. Am J Physiol Endocrinol Metab 299: E126-E130. doi:
10.1152/ajpendo.00020.2010. PubMed: 20424140.
33. Gaemers IC, Stallen JM, Kunne C, Wallner C, van Werven J et al.
(2011) Lipotoxicity and steatohepatitis in an overfed mouse model for
Adiponectin, FGF-21 and Overfeeding in Humans
PLOS ONE | www.plosone.org 8 October 2013 | Volume 8 | Issue 10 | e78864
non-alcoholic fatty liver disease. Biochim Biophys Acta 1812: 447-458.
doi:10.1016/j.bbadis.2011.01.003. PubMed: 21216282.
34. Vienberg SG, Brøns C, Nilsson E, Astrup A, Vaag A et al. (2012)
Impact of short-term high-fat feeding and insulin-stimulated FGF21
levels in subjects with low birth weight and controls. Eur J Endocrinol
167: 49-57. doi:10.1530/EJE-12-0039. PubMed: 22529197.
35. Uebanso T, Taketani Y, Yamamoto H, Amo K, Ominami H et al. (2011)
Paradoxical Regulation of Human FGF21 by Both Fasting and Feeding
Signals: Is FGF21 a Nutritional Adaptation Factor? PLOS ONE 6:
e22976. doi:10.1371/journal.pone.0022976. PubMed: 21829679.
36. Habegger KM, Stemmer K, Cheng C, Müller TD, Heppner KM et al.
(2013) Fibroblast Growth Factor 21 Mediates Specific Glucagon
Actions. Diabetes 62: 1453-1463. doi:10.2337/db12-1116. PubMed:
23305646.
37. Oppert J-M, Nadeau A, Tremblay A, Després J-P, Thériault G et al.
(1995) Plasma glucose, insulin, and glucagon before and after long-
term overfeeding in identical twins. Metabolism 44: 96-105. doi:
10.1016/0026-0495(95)90295-3. PubMed: 7854173.
38. Yoon MY, Sung JM, Song CS, Lee WY, Rhee EJ et al. (2012)
Enhanced A-FABP expression in visceral fat: potential contributor to
the progression of NASH. Clin Mol Hepatol 18: 279-286. doi:10.3350/
cmh.2012.18.3.279. PubMed: 23091808.
39. Choi KM, Kim TN, Yoo HJ, Lee KW, Cho GJ et al. (2009) Effect of
exercise training on A-FABP, lipocalin-2 and RBP4 levels in obese
women. Clin Endocrinol 70: 569-574. doi:10.1111/j.
1365-2265.2008.03374.x. PubMed: 18710473.
40. Jun LS, Siddall CP, Rosen ED (2011) A minor role for lipocalin 2 in
high-fat diet-induced glucose intolerance. Am J Physiol Endocrinol
Metab 301: E825-E835. doi:10.1152/ajpendo.00147.2011. PubMed:
21771968.
41. Guo H, Jin D, Zhang Y, Wright W, Bazuine M et al. (2010) Lipocalin-2
Deficiency Impairs Thermogenesis and Potentiates Diet-Induced Insulin
Resistance in Mice. Diabetes 59: 1376-1385. doi:10.2337/db09-1735.
PubMed: 20332347.
42. Law IKM, Xu A, Lam KSL, Berger T, Mak TW et al. (2010) Lipocalin-2
Deficiency Attenuates Insulin Resistance Associated With Aging and
Obesity. Diabetes 59: 872-882. doi:10.2337/db09-1541. PubMed:
20068130.
43. Koiou E, Tziomalos K, Katsikis I, Kandaraki EA, Kalaitzakis E et al.
(2012) Weight loss significantly reduces serum lipocalin-2 levels in
overweight and obese women with polycystic ovary syndrome. Gynecol
Endocrinol 28: 20-24. doi:10.3109/09513590.2011.588745. PubMed:
21756081.
Adiponectin, FGF-21 and Overfeeding in Humans
PLOS ONE | www.plosone.org 9 October 2013 | Volume 8 | Issue 10 | e78864
